Alfasigma S.p.a.
Clinical trials sponsored by Alfasigma S.p.a., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill could ease juvenile arthritis in kids Results expected Jun 2027 (estimated)
-
New study checks if filgotinib keeps ulcerative colitis in check Long-Term
Disease control OngoingThis study follows 509 adults with moderate to severe ulcerative colitis who are starting filgotinib, a drug also known as Jyseleca. Researchers want to see how long people stay on the treatment, how well it controls symptoms, and how it affects quality of life in everyday medica…
Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New pill could ease stiff back pain for thousands
Disease control OngoingThis phase 3 trial tests whether the drug filgotinib, taken as a daily pill, can reduce symptoms of active axial spondyloarthritis—a type of arthritis that causes back pain and stiffness. About 495 adults with the condition will receive either filgotinib (200 mg or 100 mg) or a p…
Phase 3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
1304 RA patients tracked on filgotinib: will it hold up in real life?
Disease control OngoingThis study follows over 1300 adults with moderate to severe rheumatoid arthritis who are starting filgotinib (Jyseleca) as part of their normal care. Researchers will track how long patients stay on the drug, their pain, fatigue, and daily function over two years. The goal is to …
Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Jun 26, 2026 17:02 UTC